US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
BBC Countryfile star Adam Henson's wife wrote heartbreaking goodbye letters after cancer diagnosis
Countryfile star Adam Henson has bravely opened up about his wife Charlie's pancreatic cancer diagno2024-05-22Kenya declares public holiday to mourn flood victims
NAIROBI, Kenya (AP) — Kenya’s President William Ruto has declared Friday a public holiday to mourn t2024-05-22Hong Kong court bans 'Glory to Hong Kong' song
HONG KONG (AP) — An appeals court Wednesday granted the Hong Kong government’s request to ban a popu2024-05-22Eurovision viewers SLAM 'epilepsy
Eurovision fans were left unimpressed with the frequent use of strobe lights during Tuesday night's2024-05-22Celebrity tequila brands, like George Clooney
Most popular tequila brands, including celebrity labels like Casamigos and Kendall Jenner's 818, inc2024-05-22Pennsylvania sees fewer mail ballots rejected for technicalities, a priority for election officials
HARRISBURG, Pa. (AP) — Pennsylvania election officials said Wednesday that the number of mail-in bal2024-05-22
atest comment